董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Ghenchev | 男 | Director | 38 | 未披露 | 未持股 | 2021-06-30 |
| Mario Polywka | 男 | Director | 58 | 未披露 | 未持股 | 2021-06-30 |
| Joanne Xu | 女 | Director | 43 | 未披露 | 未持股 | 2021-06-30 |
| Andrew L. Hopkins | 男 | Founder, Chief Executive Officer and Director | 49 | 未披露 | 未持股 | 2021-06-30 |
| Ben Taylor | 男 | Chief Financial Officer and Director | 43 | 未披露 | 未持股 | 2021-06-30 |
| Elizabeth Crain | 女 | Director | 56 | 未披露 | 未持股 | 2021-06-30 |
| David Nicholson | 男 | Chairman of the Board | 66 | 未披露 | 未持股 | 2021-06-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew L. Hopkins | 男 | Founder, Chief Executive Officer and Director | 49 | 未披露 | 未持股 | 2021-06-30 |
| Ben Taylor | 男 | Chief Financial Officer and Director | 43 | 未披露 | 未持股 | 2021-06-30 |
| David Hallett | 男 | Chief Operations Officer | 51 | 未披露 | 未持股 | 2021-06-30 |
| Garry Pairaudeau | 男 | Chief Technology Officer | 55 | 未披露 | 未持股 | 2021-06-30 |
董事简历
中英对照 | 中文 | 英文- Robert Ghenchev
-
Robert Ghenchev自2020年5月起担任我们的董事会成员。Ghenchev先生自2018年1月起受雇于Novo Holdings，自2019年8月起受雇于其全资子公司Novo Holdings Equity US Inc.，该公司为Novo Holdings提供某些咨询服务。他目前担任高级合伙人，负责增长股权投资。在加入Novo Holdings之前，Ghenchev先生于2010年4月至2018年1月担任伦敦Moelis&Company的高级副总裁，专注于医疗保健行业的并购。在加入Moelis之前，2007年6月至2010年4月，Ghenchev先生是伦敦德意志银行英国并购团队的一员。Ghenchev先生目前还在Tempus Labs，Inc.，Oxford Biomedica plc，Mission Bio，Inc.和MightYowl，Inc.的董事会任职。Ghenchev先生拥有J.Hons。麦吉尔大学金融和经济学学士学位，理学硕士学位。牛津大学金融经济学学位。
Robert Ghenchev,has served as a member of Tempus Ai, Inc. board of directors since May 2019 and is currently employed as Managing Partner and Head of Growth Investments at Novo Holdings A/S. Prior to joining Novo Holdings in January of 2018, Mr. Ghenchev served as a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the healthcare industry, from April 2010 to January 2018. Mr. Ghenchev also serves on the boards of directors of Exscientia plc, a Nasdaq-listed public company, Oxford Biomedica plc, a company listed on the London Stock Exchange, and other private companies. Mr. Ghenchev holds a B.A. in Economics and Finance from McGill University and an M.Sc. in Financial Economics from the University of Oxford. - Robert Ghenchev自2020年5月起担任我们的董事会成员。Ghenchev先生自2018年1月起受雇于Novo Holdings，自2019年8月起受雇于其全资子公司Novo Holdings Equity US Inc.，该公司为Novo Holdings提供某些咨询服务。他目前担任高级合伙人，负责增长股权投资。在加入Novo Holdings之前，Ghenchev先生于2010年4月至2018年1月担任伦敦Moelis&Company的高级副总裁，专注于医疗保健行业的并购。在加入Moelis之前，2007年6月至2010年4月，Ghenchev先生是伦敦德意志银行英国并购团队的一员。Ghenchev先生目前还在Tempus Labs，Inc.，Oxford Biomedica plc，Mission Bio，Inc.和MightYowl，Inc.的董事会任职。Ghenchev先生拥有J.Hons。麦吉尔大学金融和经济学学士学位，理学硕士学位。牛津大学金融经济学学位。
- Robert Ghenchev,has served as a member of Tempus Ai, Inc. board of directors since May 2019 and is currently employed as Managing Partner and Head of Growth Investments at Novo Holdings A/S. Prior to joining Novo Holdings in January of 2018, Mr. Ghenchev served as a Senior Vice President at Moelis & Company in London where he focused on mergers and acquisitions within the healthcare industry, from April 2010 to January 2018. Mr. Ghenchev also serves on the boards of directors of Exscientia plc, a Nasdaq-listed public company, Oxford Biomedica plc, a company listed on the London Stock Exchange, and other private companies. Mr. Ghenchev holds a B.A. in Economics and Finance from McGill University and an M.Sc. in Financial Economics from the University of Oxford.
- Mario Polywka
-
Mario Polywka自2017年9月起担任我们的董事会成员，自2021年6月起担任我们的审计委员会成员。Polywka博士在2018年退休之前曾担任Evotec SE的首席运营官，自2019年6月以来一直担任Evotec SE的监事会成员。Polywka博士目前还担任Forge Therapeutics Inc.，Blacksmith Medicines Inc.和Orbit Discovery Limited的董事会成员，并担任MCF Corporate Finance的高级顾问。Polywka博士曾于2015年至2016年担任Nanotether Discovery Services Limited的董事会成员（2003年至2018年），以及Glycoform Ltd.的董事会成员（2004年至2010年）。Polywka博士是牛津不对称国际OAI的创始化学家，于1991年成为化学总监，并于1996年成为董事会成员。他于1999年被任命为OAI plc的首席运营官，并于2000年被任命为首席执行官。从1989年到1991年，他担任Oxford Chirality Ltd.（OAI的前身）的高级化学家。Polywka博士在Steve Davies教授的指导下获得了牛津大学机械有机金属化学博士学位，并在Jack Baldwin爵士的指导下继续在牛津进行青霉素生物合成的博士后研究。Polywka博士是英国皇家化学学会的研究员。
Mario Polywka was appointed Member of the Supervisory Board in June 2019. Dr. Polywka also served as a member of the Management Board of Evotec AG from November 2007 to December 2018 including as Chief Operating Officer. In May 2017 Dr. Polywka became a member of the Board of Directors of Forge Therapeutics Inc. and in September 2017 he also joined the Board of Directors of Exscientia Ltd. Dr. Polywka has served as Non-Executive Director at UK biotechnology company Orbit Discovery since September 2019 and in September 2019 accepted a position as Senior Advisor at MCF Corporate Finance. He holds a doctorate degree in mechanistic organometallic chemistry from the University of Oxford. - Mario Polywka自2017年9月起担任我们的董事会成员，自2021年6月起担任我们的审计委员会成员。Polywka博士在2018年退休之前曾担任Evotec SE的首席运营官，自2019年6月以来一直担任Evotec SE的监事会成员。Polywka博士目前还担任Forge Therapeutics Inc.，Blacksmith Medicines Inc.和Orbit Discovery Limited的董事会成员，并担任MCF Corporate Finance的高级顾问。Polywka博士曾于2015年至2016年担任Nanotether Discovery Services Limited的董事会成员（2003年至2018年），以及Glycoform Ltd.的董事会成员（2004年至2010年）。Polywka博士是牛津不对称国际OAI的创始化学家，于1991年成为化学总监，并于1996年成为董事会成员。他于1999年被任命为OAI plc的首席运营官，并于2000年被任命为首席执行官。从1989年到1991年，他担任Oxford Chirality Ltd.（OAI的前身）的高级化学家。Polywka博士在Steve Davies教授的指导下获得了牛津大学机械有机金属化学博士学位，并在Jack Baldwin爵士的指导下继续在牛津进行青霉素生物合成的博士后研究。Polywka博士是英国皇家化学学会的研究员。
- Mario Polywka was appointed Member of the Supervisory Board in June 2019. Dr. Polywka also served as a member of the Management Board of Evotec AG from November 2007 to December 2018 including as Chief Operating Officer. In May 2017 Dr. Polywka became a member of the Board of Directors of Forge Therapeutics Inc. and in September 2017 he also joined the Board of Directors of Exscientia Ltd. Dr. Polywka has served as Non-Executive Director at UK biotechnology company Orbit Discovery since September 2019 and in September 2019 accepted a position as Senior Advisor at MCF Corporate Finance. He holds a doctorate degree in mechanistic organometallic chemistry from the University of Oxford.
- Joanne Xu
-
Joanne Xu自2021年4月起担任我们的董事会成员。徐女士自2020年1月以来一直是软银投资顾问的合伙人。在加入软银投资顾问之前，徐女士于2008年8月至2020年1月担任高盛亚洲地区的董事总经理。她的职业生涯始于任职Booz Allen Hamilton Inc.，担任高级顾问（从2003年到2006年）。徐女士拥有南京大学日本语言文学学士学位，早稻田大学商业硕士学位和哈佛商学院工商管理硕士学位。
Joanne Xu has served on our board of directors since April 2021. Ms. Xu has been a Partner at SoftBank Investment Advisors since January 2020. Before joining SoftBank Investment Advisors, Ms. Xu was a Managing Director at Goldman Sachs in Asia from August 2008 to January 2020. She began her career at Booz Allen Hamilton Inc. as a Senior Consultant from 2003 to 2006. Ms. Xu holds a B.A. in Japanese Language and Literature from Nanjing University, a master’s degree in Commerce from Waseda University and a M.B.A. from Harvard Business School. - Joanne Xu自2021年4月起担任我们的董事会成员。徐女士自2020年1月以来一直是软银投资顾问的合伙人。在加入软银投资顾问之前，徐女士于2008年8月至2020年1月担任高盛亚洲地区的董事总经理。她的职业生涯始于任职Booz Allen Hamilton Inc.，担任高级顾问（从2003年到2006年）。徐女士拥有南京大学日本语言文学学士学位，早稻田大学商业硕士学位和哈佛商学院工商管理硕士学位。
- Joanne Xu has served on our board of directors since April 2021. Ms. Xu has been a Partner at SoftBank Investment Advisors since January 2020. Before joining SoftBank Investment Advisors, Ms. Xu was a Managing Director at Goldman Sachs in Asia from August 2008 to January 2020. She began her career at Booz Allen Hamilton Inc. as a Senior Consultant from 2003 to 2006. Ms. Xu holds a B.A. in Japanese Language and Literature from Nanjing University, a master’s degree in Commerce from Waseda University and a M.B.A. from Harvard Business School.
- Andrew L. Hopkins
-
Andrew L.Hopkins创立了Exscientia，自2012年公司成立起担任首席执行官和董事会成员。在创立Exscientia之前，Hopkins博士从1998年到2007年在辉瑞公司工作了近10年，在学术界工作了5年。他也是邓迪大学生命科学学院的荣誉教授，在此之前，他曾于2007年至2020年担任医学信息学主席，并于2007年至2020年担任转化生物学的苏尔萨研究教授。他也曾担任Scottish Universities Life Sciences Alliance Sulsa的董事（从2011年到2016年）。Hopkins博士拥有曼彻斯特大学的一级学士学位（荣誉），在牛津大学牛津大学瓦德姆学院进行了研究生研究，并获得了牛津大学分子生物物理学的哲学博士学位。
Andrew L. Hopkins founded Exscientia and has acted as Chief Executive Officer and served on our board of directors since our inception in 2012. Prior to founding Exscientia, Dr. Hopkins spent near 10 years at Pfizer Inc., from 1998 to 2007 and 5 years in academia. He is also an honorary professor at the School of Life Sciences, University of Dundee, where he previously held the Chair of Medicinal Informatics from 2007 to 2020 and was the SULSA Research Professor of Translational Biology from 2007 to 2020. He was also the Director of Scottish Universities Life Sciences Alliance SULSA from 2011 to 2016. Dr. Hopkins holds a first class B.Sc (Hons) from the University of Manchester, conducted his graduate research at Wadham College, Oxford, University of Oxford and earned his Doctor of Philosophy degree in Molecular Biophysics from University of Oxford. - Andrew L.Hopkins创立了Exscientia，自2012年公司成立起担任首席执行官和董事会成员。在创立Exscientia之前，Hopkins博士从1998年到2007年在辉瑞公司工作了近10年，在学术界工作了5年。他也是邓迪大学生命科学学院的荣誉教授，在此之前，他曾于2007年至2020年担任医学信息学主席，并于2007年至2020年担任转化生物学的苏尔萨研究教授。他也曾担任Scottish Universities Life Sciences Alliance Sulsa的董事（从2011年到2016年）。Hopkins博士拥有曼彻斯特大学的一级学士学位（荣誉），在牛津大学牛津大学瓦德姆学院进行了研究生研究，并获得了牛津大学分子生物物理学的哲学博士学位。
- Andrew L. Hopkins founded Exscientia and has acted as Chief Executive Officer and served on our board of directors since our inception in 2012. Prior to founding Exscientia, Dr. Hopkins spent near 10 years at Pfizer Inc., from 1998 to 2007 and 5 years in academia. He is also an honorary professor at the School of Life Sciences, University of Dundee, where he previously held the Chair of Medicinal Informatics from 2007 to 2020 and was the SULSA Research Professor of Translational Biology from 2007 to 2020. He was also the Director of Scottish Universities Life Sciences Alliance SULSA from 2011 to 2016. Dr. Hopkins holds a first class B.Sc (Hons) from the University of Manchester, conducted his graduate research at Wadham College, Oxford, University of Oxford and earned his Doctor of Philosophy degree in Molecular Biophysics from University of Oxford.
- Ben Taylor
-
Ben Taylor于2020年11月加入Exscientia，担任我们的首席财务官和董事会成员。Taylor先生拥有超过20年的经验，包括15年的医疗保健投资银行业务（主要在Goldman Sachs&Co.LLC或Goldman Sachs），以及7年的生物技术和健康技术执行职务。在此期间，Taylor先生专注于生物制药行业的战略，融资，沟通，临床开发和业务开发。在加入Exscientia之前，Taylor先生于2020年4月至2020年11月担任Aetion，Inc.的临时首席财务官，该公司是一家使用真实世界数据分析来优化生物制药临床开发和商业化的健康科技公司。Taylor先生曾担任TymeTechnologies，Inc.的总裁兼首席财务官，从2017年4月至2020年8月负责该肿瘤公司的运营。泰勒先生于2016年2月至2017年3月担任巴克莱资本公司的商业制药主管兼董事总经理，并于2006年7月至2016年2月在高盛担任各种职务。他获得了布朗大学东亚研究的荣誉学士学位。
Ben Taylor serves as our Chief Financial Officer and as a member of the board of directors, having joined Exscientia in November 2020. Mr. Taylor has more than two decades of experience, including 15 years in healthcare investment banking, primarily at Goldman Sachs & Co. LLC, or Goldman Sachs, and seven years in biotech and healthtech executive roles. During this period, Mr. Taylor focused on strategy, financings, communications, clinical development and business development in the biopharmaceutical industry. Prior to joining Exscientia, Mr. Taylor was interim Chief Financial Officer at Aetion, Inc., a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation, from April 2020 to November 2020. Mr. Taylor served as President and Chief Financial Officer for Tyme Technologies, Inc., where he oversaw operations for the oncology company from April 2017 to August 2020. Mr. Taylor served as Head of Commercial Pharma, Managing Director for Barclays Capital Inc. from February 2016 to March 2017 and in a variety of roles with Goldman Sachs from July 2006 to February 2016. He received a B.A. with Honors from Brown University in East Asian Studies. - Ben Taylor于2020年11月加入Exscientia，担任我们的首席财务官和董事会成员。Taylor先生拥有超过20年的经验，包括15年的医疗保健投资银行业务（主要在Goldman Sachs&Co.LLC或Goldman Sachs），以及7年的生物技术和健康技术执行职务。在此期间，Taylor先生专注于生物制药行业的战略，融资，沟通，临床开发和业务开发。在加入Exscientia之前，Taylor先生于2020年4月至2020年11月担任Aetion，Inc.的临时首席财务官，该公司是一家使用真实世界数据分析来优化生物制药临床开发和商业化的健康科技公司。Taylor先生曾担任TymeTechnologies，Inc.的总裁兼首席财务官，从2017年4月至2020年8月负责该肿瘤公司的运营。泰勒先生于2016年2月至2017年3月担任巴克莱资本公司的商业制药主管兼董事总经理，并于2006年7月至2016年2月在高盛担任各种职务。他获得了布朗大学东亚研究的荣誉学士学位。
- Ben Taylor serves as our Chief Financial Officer and as a member of the board of directors, having joined Exscientia in November 2020. Mr. Taylor has more than two decades of experience, including 15 years in healthcare investment banking, primarily at Goldman Sachs & Co. LLC, or Goldman Sachs, and seven years in biotech and healthtech executive roles. During this period, Mr. Taylor focused on strategy, financings, communications, clinical development and business development in the biopharmaceutical industry. Prior to joining Exscientia, Mr. Taylor was interim Chief Financial Officer at Aetion, Inc., a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation, from April 2020 to November 2020. Mr. Taylor served as President and Chief Financial Officer for Tyme Technologies, Inc., where he oversaw operations for the oncology company from April 2017 to August 2020. Mr. Taylor served as Head of Commercial Pharma, Managing Director for Barclays Capital Inc. from February 2016 to March 2017 and in a variety of roles with Goldman Sachs from July 2006 to February 2016. He received a B.A. with Honors from Brown University in East Asian Studies.
- Elizabeth Crain
-
Elizabeth Crain，自2023年起担任诺基亚董事会成员。战略委员会主席和人事委员会成员。美国宾夕法尼亚大学沃顿商学院MBA，美国亚利桑那州立大学经济学理学学士。咨询合作伙伴，Consello Group。Moelis & Company联合创始人；曾担任首席运营官2007 – 2023。瑞银投资银行首席执行官办公室董事总经理2005 – 2007。瑞银投资银行部美洲专营权2001– 2005年首席运营官兼首席行政官。投资负责人，McCown De Leeuw & Company 2000 – 2001。Investment Principal，摩根士丹利 Capital Partners 1997 – 2000。美林投资银行副总裁，1994 – 1997。摩根大通证券1992 – 1994年投资银行部协理。分析师，Merrill Lynch & Co. 1988 – 1990。伦敦皇家学院信托基金名誉受托人。Exscientia PLC董事会成员2021 – 2024年。Moelis & Company董事会成员2017 – 2021年。
Elizabeth Crain,Nokia Board member since 2023. Chair of the Strategy Committee and member of the Personnel Committee. MBA, the Wharton School at the University of Pennsylvania, United States. Bachelor of Science in Economics, Arizona State University, United States. Advisory Partner, the Consello Group. Co-Founder of Moelis & Company; served as the Chief Operating Officer 2007–2023. Managing Director, Office of the CEO at UBS Investment Bank 2005–2007. Chief Operating Officer and Chief Administrative Officer of the UBS Investment Banking Department Americas franchise 2001–2005. Investment Principal, McCown De Leeuw & Company 2000–2001. Investment Principal, Morgan Stanley Capital Partners 1997–2000. Vice President, Investment Banking, Merrill Lynch & Co. 1994–1997. Associate, Investment Banking, J.P. Morgan Securities 1992–1994. Analyst, Merrill Lynch & Co. 1988–1990. Trustee Emeritus, The Royal Academy Trust, London. Member of the Board of Directors of Exscientia Plc 2021–2024. Member of the Board of Directors of Moelis & Company 2017–2021. - Elizabeth Crain，自2023年起担任诺基亚董事会成员。战略委员会主席和人事委员会成员。美国宾夕法尼亚大学沃顿商学院MBA，美国亚利桑那州立大学经济学理学学士。咨询合作伙伴，Consello Group。Moelis & Company联合创始人；曾担任首席运营官2007 – 2023。瑞银投资银行首席执行官办公室董事总经理2005 – 2007。瑞银投资银行部美洲专营权2001– 2005年首席运营官兼首席行政官。投资负责人，McCown De Leeuw & Company 2000 – 2001。Investment Principal，摩根士丹利 Capital Partners 1997 – 2000。美林投资银行副总裁，1994 – 1997。摩根大通证券1992 – 1994年投资银行部协理。分析师，Merrill Lynch & Co. 1988 – 1990。伦敦皇家学院信托基金名誉受托人。Exscientia PLC董事会成员2021 – 2024年。Moelis & Company董事会成员2017 – 2021年。
- Elizabeth Crain,Nokia Board member since 2023. Chair of the Strategy Committee and member of the Personnel Committee. MBA, the Wharton School at the University of Pennsylvania, United States. Bachelor of Science in Economics, Arizona State University, United States. Advisory Partner, the Consello Group. Co-Founder of Moelis & Company; served as the Chief Operating Officer 2007–2023. Managing Director, Office of the CEO at UBS Investment Bank 2005–2007. Chief Operating Officer and Chief Administrative Officer of the UBS Investment Banking Department Americas franchise 2001–2005. Investment Principal, McCown De Leeuw & Company 2000–2001. Investment Principal, Morgan Stanley Capital Partners 1997–2000. Vice President, Investment Banking, Merrill Lynch & Co. 1994–1997. Associate, Investment Banking, J.P. Morgan Securities 1992–1994. Analyst, Merrill Lynch & Co. 1988–1990. Trustee Emeritus, The Royal Academy Trust, London. Member of the Board of Directors of Exscientia Plc 2021–2024. Member of the Board of Directors of Moelis & Company 2017–2021.
- David Nicholson
-
David Nicholson是本公司的董事，并在2012年3月5日加入Bayer CropScience执行委员会作为研究及发展部主管，负责将公司的研发活动整合成一个全球性的组织。他毕业于药理学，1975年从University of Manchester获得他的学士学位。1980年获得University of Wales博士学位。在1978年和1988年之间，他曾在British company Beecham-Wülfing in Gronau, Germany医药工业工作。他作为一个多学科项目组组长的主要重点是发展心血管药。从1988年至2007年，他任职于 Akzo Nobel Organon业务部多个职位，在英国，荷兰和美国，从而积攒了他的资历。最终，他成为研发部执行副总裁，以及Organon Executive Management Committee成员。他实施的变革计划，导致研发效益最大化，确保顾客为关注焦点，并建立创新药物具有竞争力的管道。 2007年，他跳槽去了Schering-Plough, Kenilworth, New Jersey，担任高级副总裁，负责全球项目管理和用药安全。从2009年到2011年12月，他担任Merck in Rahway, New Jersey副总裁，向Merck R&D总裁报告。作为一个整合团队成员，2007年，他在Organon BioSciences战略并购，Dutch chemical giant Akzo-Nobel, and Schering-Plough人类和动物健康业务 发挥了作用。在2009年，他在Schering-Plough and Merck 。他是目前在多个生物技术公司董事会成员，包括Actinium Pharmaceuticals。
David Nicholson,serves as Actinium Pharmaceuticals, Inc. Lead Independent Director of Actinium Pharmaceuticals, Inc. Board and has been a Director of the Company since 2008. Dr. Nicholson is also a member of Actinium Pharmaceuticals, Inc. Compensation Committee and Actinium Pharmaceuticals, Inc. Nominating and Corporate Governance Committee. Since March 2015, Dr. Nicholson served as Executive Vice President and Chief R&D Officer of Allergan, which was acquired by Abbvie in May 2020. In August 2014, Dr. Nicholson joined Allergan (previously known as Actavis plc and Forest Laboratories, Inc.) as senior vice president, Actavis Global Brands R&D. From March 2012 to August 2014, Dr. Nicholson was on the executive committee of Bayer CropScience as head of research & development responsible for the integration of the company's R&D activities into one global organization. Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-Wülfing in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs.From 1988-2007, Dr. Nicholson held various positions of increasing seniority in the UK, the Netherlands and the U.S. with Organon, a business unit of Akzo Nobel. Ultimately, he became executive vice president, research & development, and member of the Organon Executive Management Committee. He implemented change programs, leading to maximizing effectiveness in research & development, ensuring customer focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey as senior vice president, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he was vice president licensing and knowledge management at Merck in Rahway, New Jersey, reporting to the president of Merck R&D. As an integration team member, Dr. Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009. - David Nicholson是本公司的董事，并在2012年3月5日加入Bayer CropScience执行委员会作为研究及发展部主管，负责将公司的研发活动整合成一个全球性的组织。他毕业于药理学，1975年从University of Manchester获得他的学士学位。1980年获得University of Wales博士学位。在1978年和1988年之间，他曾在British company Beecham-Wülfing in Gronau, Germany医药工业工作。他作为一个多学科项目组组长的主要重点是发展心血管药。从1988年至2007年，他任职于 Akzo Nobel Organon业务部多个职位，在英国，荷兰和美国，从而积攒了他的资历。最终，他成为研发部执行副总裁，以及Organon Executive Management Committee成员。他实施的变革计划，导致研发效益最大化，确保顾客为关注焦点，并建立创新药物具有竞争力的管道。 2007年，他跳槽去了Schering-Plough, Kenilworth, New Jersey，担任高级副总裁，负责全球项目管理和用药安全。从2009年到2011年12月，他担任Merck in Rahway, New Jersey副总裁，向Merck R&D总裁报告。作为一个整合团队成员，2007年，他在Organon BioSciences战略并购，Dutch chemical giant Akzo-Nobel, and Schering-Plough人类和动物健康业务 发挥了作用。在2009年，他在Schering-Plough and Merck 。他是目前在多个生物技术公司董事会成员，包括Actinium Pharmaceuticals。
- David Nicholson,serves as Actinium Pharmaceuticals, Inc. Lead Independent Director of Actinium Pharmaceuticals, Inc. Board and has been a Director of the Company since 2008. Dr. Nicholson is also a member of Actinium Pharmaceuticals, Inc. Compensation Committee and Actinium Pharmaceuticals, Inc. Nominating and Corporate Governance Committee. Since March 2015, Dr. Nicholson served as Executive Vice President and Chief R&D Officer of Allergan, which was acquired by Abbvie in May 2020. In August 2014, Dr. Nicholson joined Allergan (previously known as Actavis plc and Forest Laboratories, Inc.) as senior vice president, Actavis Global Brands R&D. From March 2012 to August 2014, Dr. Nicholson was on the executive committee of Bayer CropScience as head of research & development responsible for the integration of the company's R&D activities into one global organization. Dr. Nicholson graduated in pharmacology, earning his B.Sc. from the University of Manchester (1975) and his Ph.D. from the University of Wales (1980). Between 1978 and 1988, Dr. Nicholson worked in the pharmaceutical industry for the British company Beecham-Wülfing in Gronau, Germany. The main emphasis of his activities as group leader in a multidisciplinary project group was the development of cardiovascular drugs.From 1988-2007, Dr. Nicholson held various positions of increasing seniority in the UK, the Netherlands and the U.S. with Organon, a business unit of Akzo Nobel. Ultimately, he became executive vice president, research & development, and member of the Organon Executive Management Committee. He implemented change programs, leading to maximizing effectiveness in research & development, ensuring customer focus and the establishment of a competitive pipeline of innovative drugs. In 2007, Dr. Nicholson transferred to Schering-Plough, Kenilworth, New Jersey as senior vice president, responsible for Global Project Management and Drug Safety. From 2009 to December 2011, he was vice president licensing and knowledge management at Merck in Rahway, New Jersey, reporting to the president of Merck R&D. As an integration team member, Dr. Nicholson played a role in the strategic mergers of Organon BioSciences, the human and animal health business of Dutch chemical giant Akzo-Nobel, and Schering-Plough in 2007 as well as of Schering-Plough and Merck in 2009.
高管简历
中英对照 | 中文 | 英文- Andrew L. Hopkins
Andrew L.Hopkins创立了Exscientia，自2012年公司成立起担任首席执行官和董事会成员。在创立Exscientia之前，Hopkins博士从1998年到2007年在辉瑞公司工作了近10年，在学术界工作了5年。他也是邓迪大学生命科学学院的荣誉教授，在此之前，他曾于2007年至2020年担任医学信息学主席，并于2007年至2020年担任转化生物学的苏尔萨研究教授。他也曾担任Scottish Universities Life Sciences Alliance Sulsa的董事（从2011年到2016年）。Hopkins博士拥有曼彻斯特大学的一级学士学位（荣誉），在牛津大学牛津大学瓦德姆学院进行了研究生研究，并获得了牛津大学分子生物物理学的哲学博士学位。
Andrew L. Hopkins founded Exscientia and has acted as Chief Executive Officer and served on our board of directors since our inception in 2012. Prior to founding Exscientia, Dr. Hopkins spent near 10 years at Pfizer Inc., from 1998 to 2007 and 5 years in academia. He is also an honorary professor at the School of Life Sciences, University of Dundee, where he previously held the Chair of Medicinal Informatics from 2007 to 2020 and was the SULSA Research Professor of Translational Biology from 2007 to 2020. He was also the Director of Scottish Universities Life Sciences Alliance SULSA from 2011 to 2016. Dr. Hopkins holds a first class B.Sc (Hons) from the University of Manchester, conducted his graduate research at Wadham College, Oxford, University of Oxford and earned his Doctor of Philosophy degree in Molecular Biophysics from University of Oxford.- Andrew L.Hopkins创立了Exscientia，自2012年公司成立起担任首席执行官和董事会成员。在创立Exscientia之前，Hopkins博士从1998年到2007年在辉瑞公司工作了近10年，在学术界工作了5年。他也是邓迪大学生命科学学院的荣誉教授，在此之前，他曾于2007年至2020年担任医学信息学主席，并于2007年至2020年担任转化生物学的苏尔萨研究教授。他也曾担任Scottish Universities Life Sciences Alliance Sulsa的董事（从2011年到2016年）。Hopkins博士拥有曼彻斯特大学的一级学士学位（荣誉），在牛津大学牛津大学瓦德姆学院进行了研究生研究，并获得了牛津大学分子生物物理学的哲学博士学位。
- Andrew L. Hopkins founded Exscientia and has acted as Chief Executive Officer and served on our board of directors since our inception in 2012. Prior to founding Exscientia, Dr. Hopkins spent near 10 years at Pfizer Inc., from 1998 to 2007 and 5 years in academia. He is also an honorary professor at the School of Life Sciences, University of Dundee, where he previously held the Chair of Medicinal Informatics from 2007 to 2020 and was the SULSA Research Professor of Translational Biology from 2007 to 2020. He was also the Director of Scottish Universities Life Sciences Alliance SULSA from 2011 to 2016. Dr. Hopkins holds a first class B.Sc (Hons) from the University of Manchester, conducted his graduate research at Wadham College, Oxford, University of Oxford and earned his Doctor of Philosophy degree in Molecular Biophysics from University of Oxford.
- Ben Taylor
Ben Taylor于2020年11月加入Exscientia，担任我们的首席财务官和董事会成员。Taylor先生拥有超过20年的经验，包括15年的医疗保健投资银行业务（主要在Goldman Sachs&Co.LLC或Goldman Sachs），以及7年的生物技术和健康技术执行职务。在此期间，Taylor先生专注于生物制药行业的战略，融资，沟通，临床开发和业务开发。在加入Exscientia之前，Taylor先生于2020年4月至2020年11月担任Aetion，Inc.的临时首席财务官，该公司是一家使用真实世界数据分析来优化生物制药临床开发和商业化的健康科技公司。Taylor先生曾担任TymeTechnologies，Inc.的总裁兼首席财务官，从2017年4月至2020年8月负责该肿瘤公司的运营。泰勒先生于2016年2月至2017年3月担任巴克莱资本公司的商业制药主管兼董事总经理，并于2006年7月至2016年2月在高盛担任各种职务。他获得了布朗大学东亚研究的荣誉学士学位。
Ben Taylor serves as our Chief Financial Officer and as a member of the board of directors, having joined Exscientia in November 2020. Mr. Taylor has more than two decades of experience, including 15 years in healthcare investment banking, primarily at Goldman Sachs & Co. LLC, or Goldman Sachs, and seven years in biotech and healthtech executive roles. During this period, Mr. Taylor focused on strategy, financings, communications, clinical development and business development in the biopharmaceutical industry. Prior to joining Exscientia, Mr. Taylor was interim Chief Financial Officer at Aetion, Inc., a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation, from April 2020 to November 2020. Mr. Taylor served as President and Chief Financial Officer for Tyme Technologies, Inc., where he oversaw operations for the oncology company from April 2017 to August 2020. Mr. Taylor served as Head of Commercial Pharma, Managing Director for Barclays Capital Inc. from February 2016 to March 2017 and in a variety of roles with Goldman Sachs from July 2006 to February 2016. He received a B.A. with Honors from Brown University in East Asian Studies.- Ben Taylor于2020年11月加入Exscientia，担任我们的首席财务官和董事会成员。Taylor先生拥有超过20年的经验，包括15年的医疗保健投资银行业务（主要在Goldman Sachs&Co.LLC或Goldman Sachs），以及7年的生物技术和健康技术执行职务。在此期间，Taylor先生专注于生物制药行业的战略，融资，沟通，临床开发和业务开发。在加入Exscientia之前，Taylor先生于2020年4月至2020年11月担任Aetion，Inc.的临时首席财务官，该公司是一家使用真实世界数据分析来优化生物制药临床开发和商业化的健康科技公司。Taylor先生曾担任TymeTechnologies，Inc.的总裁兼首席财务官，从2017年4月至2020年8月负责该肿瘤公司的运营。泰勒先生于2016年2月至2017年3月担任巴克莱资本公司的商业制药主管兼董事总经理，并于2006年7月至2016年2月在高盛担任各种职务。他获得了布朗大学东亚研究的荣誉学士学位。
- Ben Taylor serves as our Chief Financial Officer and as a member of the board of directors, having joined Exscientia in November 2020. Mr. Taylor has more than two decades of experience, including 15 years in healthcare investment banking, primarily at Goldman Sachs & Co. LLC, or Goldman Sachs, and seven years in biotech and healthtech executive roles. During this period, Mr. Taylor focused on strategy, financings, communications, clinical development and business development in the biopharmaceutical industry. Prior to joining Exscientia, Mr. Taylor was interim Chief Financial Officer at Aetion, Inc., a healthtech company using real world data analytics to optimise biopharma clinical development and commercialisation, from April 2020 to November 2020. Mr. Taylor served as President and Chief Financial Officer for Tyme Technologies, Inc., where he oversaw operations for the oncology company from April 2017 to August 2020. Mr. Taylor served as Head of Commercial Pharma, Managing Director for Barclays Capital Inc. from February 2016 to March 2017 and in a variety of roles with Goldman Sachs from July 2006 to February 2016. He received a B.A. with Honors from Brown University in East Asian Studies.
- David Hallett
David Hallett自2020年1月起担任我们的首席运营官。Hallett博士在药物发现和联盟管理方面拥有超过20年的经验。在加入Exscientia之前，Hallett博士于2005年9月至2019年12月担任Evotec化学执行副总裁兼联盟管理执行副总裁。Hallett博士接受了药物化学家的培训，并在默克制药公司担任研究员。他拥有剑桥大学自然科学学士学位，曼彻斯特大学合成有机化学博士学位，并曾是德克萨斯大学奥斯汀分校合成有机化学博士后研究员。
David Hallett has served as our Chief Operations Officer since January 2020. Dr. Hallett has more than two decades of experience in drug discovery and alliance management. Prior to joining Exscientia, Dr. Hallett served as Executive Vice President of Chemistry and Executive Vice President of Alliance Management at Evotec from September 2005 to December 2019. Dr. Hallett trained as a medicinal chemist and served as a Research Fellow at Merck & Co., Inc. He holds a B.A. from the University of Cambridge in Natural Sciences, a Ph.D. from the University of Manchester in Synthetic Organic Chemistry and was a post-doctoral fellow in Synthetic Organic Chemistry at the University of Texas Austin.- David Hallett自2020年1月起担任我们的首席运营官。Hallett博士在药物发现和联盟管理方面拥有超过20年的经验。在加入Exscientia之前，Hallett博士于2005年9月至2019年12月担任Evotec化学执行副总裁兼联盟管理执行副总裁。Hallett博士接受了药物化学家的培训，并在默克制药公司担任研究员。他拥有剑桥大学自然科学学士学位，曼彻斯特大学合成有机化学博士学位，并曾是德克萨斯大学奥斯汀分校合成有机化学博士后研究员。
- David Hallett has served as our Chief Operations Officer since January 2020. Dr. Hallett has more than two decades of experience in drug discovery and alliance management. Prior to joining Exscientia, Dr. Hallett served as Executive Vice President of Chemistry and Executive Vice President of Alliance Management at Evotec from September 2005 to December 2019. Dr. Hallett trained as a medicinal chemist and served as a Research Fellow at Merck & Co., Inc. He holds a B.A. from the University of Cambridge in Natural Sciences, a Ph.D. from the University of Manchester in Synthetic Organic Chemistry and was a post-doctoral fellow in Synthetic Organic Chemistry at the University of Texas Austin.
- Garry Pairaudeau
Garry Pairaudeau自2020年11月起担任我们的首席技术官。Pairaudeau博士在药物研究和技术领导领域拥有超过25年的经验。在加入Exscientia之前，Pairaudeau博士于2017年1月至2020年11月担任AstraZeneca PLC的HIT发现主管，并于2014年10月至2017年1月担任外部科学主管。他也是全球化学领导者网络的主席。Pairaudeau博士拥有南安普敦大学化学学士学位和博士学位，并曾是加州大学欧文分校的博士后研究员。
Garry Pairaudeau has served as our Chief Technology Officer since November 2020. Dr. Pairaudeau has more than 25 years of experience in the drug hunting and technology leadership space. Prior to joining Exscientia, Dr. Pairaudeau served as Head of Hit Discovery at AstraZeneca plc from January 2017 to November 2020 and as Head of External Sciences from October 2014 to January 2017. He was also Chair of the Global Chemistry Leaders Network. Dr. Pairaudeau holds a Bachelor of Science and Ph.D. in Chemistry from Southampton University and was a post-doctoral fellow at the University of California, Irvine.- Garry Pairaudeau自2020年11月起担任我们的首席技术官。Pairaudeau博士在药物研究和技术领导领域拥有超过25年的经验。在加入Exscientia之前，Pairaudeau博士于2017年1月至2020年11月担任AstraZeneca PLC的HIT发现主管，并于2014年10月至2017年1月担任外部科学主管。他也是全球化学领导者网络的主席。Pairaudeau博士拥有南安普敦大学化学学士学位和博士学位，并曾是加州大学欧文分校的博士后研究员。
- Garry Pairaudeau has served as our Chief Technology Officer since November 2020. Dr. Pairaudeau has more than 25 years of experience in the drug hunting and technology leadership space. Prior to joining Exscientia, Dr. Pairaudeau served as Head of Hit Discovery at AstraZeneca plc from January 2017 to November 2020 and as Head of External Sciences from October 2014 to January 2017. He was also Chair of the Global Chemistry Leaders Network. Dr. Pairaudeau holds a Bachelor of Science and Ph.D. in Chemistry from Southampton University and was a post-doctoral fellow at the University of California, Irvine.